January 2025 – Page 15

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

4 months ago talkbio0Tagged Acquisition, Biopharma, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A

Tenpoint Therapeutics Prepares for 2026 Market Launch Following Successful Phase 3 Trial of BRIMOCHOL PF for Presbyopia Treatment

4 months ago talkbio0Tagged BRIMOCHOL, fluorouracil/melphalan, launch, Market, Phase 3 trial, presbyopia, Tenpoint Therapeutics

Tenpoint Therapeutics, BRIMOCHOL PF, Presbyopia treatment, Phase 3 trial, Combination eye drop, 2026 market launch

Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy

4 months ago talkbio0Tagged Age related macular degeneration, Bausch, Cities, Geographic Atrophy, Lomb, Ophthalmologic diseases, RNA Interference, strategic collaboration

Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

4 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

4 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

4 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners